Gilead and AbbVie HCV meds face off in hard-to-treat

Share this article:
Gilead and AbbVie HCV meds face off in hard-to-treat
Gilead and AbbVie HCV meds face off in hard-to-treat

The 49th International Liver Congress in London this past weekend may have kicked off a new point of contention in the HCV landscape, as new data debuted from AbbVie's investigational combo regimen (ABT-450/ritovanir +ABT-267 and ABT-133) and Gilead's Sovaldi.

The data showed each treatment's effect in HCV patients with cirrhosis (scarring of the liver) thus far; Gilead's data also included two studies of patients with recurring and severe recurring HCV after a liver transplant.

In one of Gilead's two Phase-II trials, 21 out of 22 enrolled patients achieved “virologic suppression on treatment,” or the drug lowered patients RNA count (the virus's genetic building blocks) after taking Sovaldi and ribavirin for 24 weeks. Gilead stated that it will “determine their SVR12 [or cure] rate, after 48 weeks of therapy."

The second reported trial, which evaluated patients with recurrent HCV after a liver transplant, saw 70% (28 out of 40) of patients enrolled achieve SVR12. The majority of patients had genotype 1 of the virus (GT1).

Gilead's last reported trial—a "compassionate access" study—among 104 post-transplant patients “who exhausted all other treatment options,” according to the drugmaker, saw 62% of those patients achieve SVR12 with Sovaldi and ribavirin. Some patients also received peglayted interferon, Gilead noted.

AbbVie's Phase-III trial of GT1 patients with cirrhosis also saw strong results—and spanned hundreds of patients compared to the Gilead trial's smaller sample size.

AbbVie's overall data showed SVR12 rates of 91% (191 out of 208) over 12 weeks and 95.9% (165 out of 172) in patients over 24 weeks of therapy. When the results are broken out further, 90% (110 out of 122) of patients who were treatment-experienced achieved SVR12, while 94% of patients who were new to therapy (81 out of 86) achieved SVR12.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...